عنوان مقاله [English]
نویسندگان [English]چکیده [English]
: In this study, Trastuzumab was labeled with 177Lu, and its dosimetric calculation was performed considering the assessment of the absorbed dose in the organs of human body. 177Lu chloride was prepared after 7 days irradiation of enriched Lu2O3 in the Tehran Research Reactor at the thermal neutron flux of 4×1013 cm-2 s-1, and the specific activity of 70-80 GBq/mg. 177Lu-DOTA-Trastuzumab was obtained with an overall radiochemical purity of >98% under the optimized conditions. Biodistribution studies of the radioimmunoconjugate in normal rats were carried up to 168 h. Relative organ mass extrapolation method was used for calculation of the human absorbed dose. Because of the highest accumulation activity in reticuloendothelial system, liver and spleen have received the maximum dose of 0.95 and 0.89 mSv/MBq, respectively.
 American Cancer Society. Cancer Facts and Figures. Atlanta, GA: (2009).
 J. Baselga, L. Norton, J. Albanell, Y.M. Kim, J. Mendelsohn, Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts, Cancer. Res. 58 (1998) 2825–2831.
 H.B. Muss, A.D. Thor, D.A. Berry, C-Erbb-2 Expression and response to adjuvant therapy in women with node-positive early breast cancer, N. Eng. J. Med. 330 (1994) 1260–1266.
 M.G. Stabin, M. Tagesson, S.R. Thomas, M. Ljungberg, S.E. Strand, Radiation dosimetry in nuclear medicine, applied radiation and isotopes, (1999) 5073-5087.
 J.J. Bevelacqua, Internal Dosimetry Primer, radiation protection management, 22 (2005) No.5.
 H. Uusijarvi, P. Bernhardt, Translation dosimetry results of preclinical radionuclide therapy to clinical situations: influence of photon irradiation. cancer biotherapy and radiopharmaceuticals, 22 (2007) No. 2.
 S. Palm, R.M. Enmon, C. Matei, K.S. Kolbert, S. Xu, P.B. Zanzonico, R.L. Finn, J.A. Koutcher, S.M. Larson, G. Sgouros, Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI, J. Nucl. Med. 44 (2003) 1148-1155.
 T.A. Deterding, J.R. Voraw, C.K. Wang, D. Eshima, L. Eshima, R. Keil, E. Malveaux, C.D. Kilts, M.M. Goodman, J.M. Hoffman, Biodistribution and radiation dosimetry of the dopamine transporter, ligand. J. Nucl. Med. 42 (2001) 376-381.
 A. Bahrami-Samani, M. Ghannadi-Maragheh, A.R. Jalilian, H. Yousefnia, J. Garousi, S. Moradkhani, Development of 153Sm-DTPA-rituximabfor radioimmunotherapy, NUKLEONIKA, 54 (2009) 271−277.
 S. Zolghadri, A.R. Jalilian, H. Yousefnia, A. Bahrami-Samani, S. Shirvani-Arani, M. Ghannadi-Maragheh, Radiochim. Preparation and quality control of 166Ho-DTPA-antiCD20 for radioimmunotherapy. Acta 99 (2011) 1–6.
 S. Banerjee, T. Das, S. Chakraborty, G. Samuel, A. Korde, S. Sri-Vastava, M. Venkatesha, M.R.A. Pillai, 177Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy, Nucl. Med. Biol. 31 (2004) 753–759.
 W.S. Snyder, M.R. Ford, G.G. Warner, S.B. Watson, "S" absorbed dose per unit cumulated activity for selected radionuclides and organs, (1975) Nm/mird pamphlet No.11.
 R.B. Sparks, B. Aydogan, Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose. Sixth International Radiopharmaceutical Dosimetry Symposium Oak Ridge, TN: Oak Ridge Associated Universities. (1996) 705–716.
 OLINDA-Organ Level Internal Dose Assessment Code (Version 1.1), copyright Vanderbilt University, (2007).
 Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values, ICRP PUBLICATION 89 (2002) 18.
 E. Radfar, A.R. Jalilian, H. Yousefnia, A. Bahrami-Samani, M. Ghannad-Maragheh, A comparative study of preliminary dosimetry for human based on distribution data in rats with 111In, 90Y, 153Sm, and 177Lu labeled rituximab, Nucl. Tech. Radiat. Protec. 27 (2012) 144-151.
 H.F. Van Brocklin, Radiopharmaceuticals for Drug Development: United States Regulatory Perspective, Current Radiopharmaceuticals, 1 (2008) 2-6.
 U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, Guidance for Industry Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals (CDER), Pharmacology and Toxicology, (2011).